Osteopontin identified as colon cancer tumor progression marker

Deepak Agrawal, Tingan Chen, Rosalyn Irby, John Quackenbush, Ann F. Chambers, Marianna Szabo, Alan Cantor, Domenico Coppola, Timothy J. Yeatman

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Identifying molecular markers for colon cancer is a top priority. Using a pooled sample approach with Affymetrix GeneChip technology, we assayed colon cancers derived from a series of clinical stages to identify molecular markers of potential prognostic value. Of 12 000 genes assessed, osteopontin emerged as the leading candidate tumor progression marker. Osteopontin is a secreted glycoprotein known to bind integrins and CD44. Its actual molecular function remains elusive but its increased expression correlates strongly with tumor progression.

Original languageEnglish (US)
Pages (from-to)1041-1043
Number of pages3
JournalComptes Rendus - Biologies
Volume326
Issue number10-11
DOIs
StatePublished - Jan 1 2003

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Agrawal, D., Chen, T., Irby, R., Quackenbush, J., Chambers, A. F., Szabo, M., Cantor, A., Coppola, D., & Yeatman, T. J. (2003). Osteopontin identified as colon cancer tumor progression marker. Comptes Rendus - Biologies, 326(10-11), 1041-1043. https://doi.org/10.1016/j.crvi.2003.09.007